ZBH vs GMED

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 21, 2026

ZBH

39.4
AI Score
VS
GMED Wins

GMED

46.3
AI Score

Investment Advisor Scores

ZBH

39score
Recommendation
SELL

GMED

46score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ZBH GMED Winner
Revenue 4.26B 1.55B ZBH
Net Income 436.50M 275.87M ZBH
Net Margin 10.2% 17.8% GMED
Operating Income 699.20M 332.82M ZBH
ROE 3.5% 5.8% GMED
ROA 1.9% 5.0% GMED
Total Assets 22.80B 5.49B ZBH
Cash 410.00M 507.75M GMED
Current Ratio 1.69 4.62 GMED
Free Cash Flow 716.70M 339.32M ZBH

Relative Price Performance (Last 90 Days)

ZBH 1M: +0.9% · 3M: +5.8% GMED 1M: +4.6% · 3M: +4.3%

Current Technical Phase

ZBH

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 56

RSI (14): 55.8 · Price: $94.86

GMED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 57

RSI (14): 57.1 · Price: $78.68

Fundamentals Snapshot

Metric ZBH GMED
Market Cap — —
Forward P/E 10.5 14.6
Trailing P/E 23.3 20.2
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.7% 0.7%
Operating Margin 0.2% 0.2%
EPS 4.12 3.90
Dividend Yield 0.01% —

Frequently Asked Questions

Based on our detailed analysis, GMED is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.